Literature DB >> 26560017

Responsiveness, Sensitivity, and Minimally Detectable Difference of the Graded and Redefined Assessment of Strength, Sensibility, and Prehension, Version 1.0.

Sukhvinder Kalsi-Ryan1,2,3,4,5, Dorcas Beaton6,7,2,8, Henry Ahn9,2,8,5, Heather Askes5,10, Brian Drew5, Armin Curt11,5, Milos R Popovic7,12,2,4,5, Justin Wang3, Mary C Verrier1,7,2,4,5, Michael G Fehlings9,2,3,4,5.   

Abstract

As spinal cord injury (SCI) trials begin to involve subjects with acute cervical SCI, establishing the property of an upper limb outcome measure to detect change over time is critical for its usefulness in clinical trials. The objectives of this study were to define responsiveness, sensitivity, and minimally detectable difference (MDD) of the Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP). An observational, longitudinal study was conducted. International Standards of Neurological Classification of SCI (ISNCSCI), GRASSP, Capabilities of Upper Extremity Questionnaire (CUE-Q), and Spinal Cord Independence Measure (SCIM) were administered 0-10 days, 1, 3, 6, and 12 months post-injury. Standardized Response Means (SRM) for GRASSP and ISNCSCI measures were calculated. Longitudinal construct validity was calculated using Pearson correlation coefficients. Smallest real difference for all subtests was calculated to define the MDD values for all GRASSP subtests. Longitudinal construct validity demonstrated GRASSP and all external measures to be responsive to neurological change for 1 year post-injury. SRM values for the GRASSP subtests ranged from 0.25 to 0.85 units greater than that for ISNCSCI strength and sensation, SCIM-SS, and CUE-Q. MDD values for GRASSP subtests ranged from 2-5 points. GRASSP demonstrates good responsiveness and excellent sensitivity that is superior to ISNCSCI and SCIM III. MDD values are useful in the evaluation of interventions in both clinical and research settings. The responsiveness and sensitivity of GRASSP make it a valuable condition-specific measure in tetraplegia, where changes in upper limb neurological and functional outcomes are essential for evaluating the efficacy of interventions.

Entities:  

Mesh:

Year:  2015        PMID: 26560017     DOI: 10.1089/neu.2015.4217

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  14 in total

1.  Evaluation of the graded redefined assessment of strength, sensibility and prehension (GRASSP) in children with tetraplegia.

Authors:  M J Mulcahey; Christina Calhoun Thielen; Kathryn Dent; Rebecca Sinko; Cristina Sadowsky; Rebecca Martin; Lawrence C Vogel; Loren Davidson; Heather Taylor; Jackie Bultman; John Gaughan
Journal:  Spinal Cord       Date:  2018-03-26       Impact factor: 2.772

2.  The natural course of passive tenodesis grip in individuals with spinal cord injury with preserved wrist extension power but paralyzed fingers and thumbs.

Authors:  Hae Yoon Jung; Jieun Lee; Hyung Ik Shin
Journal:  Spinal Cord       Date:  2018-05-22       Impact factor: 2.772

3.  Comparison of Responsiveness and Minimal Clinically Important Difference of the Capabilities of Upper Extremity Test (CUE-T) and the Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP).

Authors:  Ralph J Marino; Rebecca Sinko; Anne Bryden; Deborah Backus; David Chen; Gregory A Nemunaitis; Benjamin E Leiby
Journal:  Top Spinal Cord Inj Rehabil       Date:  2018

4.  Predicting task performance from upper extremity impairment measures after cervical spinal cord injury.

Authors:  J Zariffa; A Curt; M C Verrier; M G Fehlings; S Kalsi-Ryan
Journal:  Spinal Cord       Date:  2016-05-31       Impact factor: 2.772

5.  The graded redefined assessment of strength sensibility and prehension version 2 (GV2): Psychometric properties.

Authors:  Sukhvinder Kalsi-Ryan; Colin Chan; Mary Verrier; Armin Curt; Michael Fehlings; Marc Bolliger; Inge-Marie Velstra
Journal:  J Spinal Cord Med       Date:  2019-10       Impact factor: 1.985

6.  Transcutaneous Electrical Spinal Stimulation Promotes Long-Term Recovery of Upper Extremity Function in Chronic Tetraplegia.

Authors:  Fatma Inanici; Soshi Samejima; Parag Gad; V Reggie Edgerton; Christoph P Hofstetter; Chet T Moritz
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2018-06       Impact factor: 3.802

7.  Brain-computer interface-triggered functional electrical stimulation therapy for rehabilitation of reaching and grasping after spinal cord injury: a feasibility study.

Authors:  Lazar I Jovanovic; Naaz Kapadia; Vera Zivanovic; Hope Jervis Rademeyer; Mohammad Alavinia; Colleen McGillivray; Sukhvinder Kalsi-Ryan; Milos R Popovic; Cesar Marquez-Chin
Journal:  Spinal Cord Ser Cases       Date:  2021-03-19

Review 8.  Considerations and recommendations for selection and utilization of upper extremity clinical outcome assessments in human spinal cord injury trials.

Authors:  Linda A T Jones; Anne Bryden; Tracey L Wheeler; Keith E Tansey; Kim D Anderson; Michael S Beattie; Andrew Blight; Armin Curt; Edelle Field-Fote; James D Guest; Jane Hseih; Lyn B Jakeman; Sukhvinder Kalsi-Ryan; Laura Krisa; Daniel P Lammertse; Benjamin Leiby; Ralph Marino; Jan M Schwab; Giorgio Scivoletto; David S Tulsky; Ed Wirth; José Zariffa; Naomi Kleitman; Mary Jane Mulcahey; John D Steeves
Journal:  Spinal Cord       Date:  2017-12-28       Impact factor: 2.772

9.  Development of Reaching, Grasping & Manipulation indicators to advance the quality of spinal cord injury rehabilitation: SCI-High Project.

Authors:  Sukhvinder Kalsi-Ryan; Naaz Kapadia; Dany H Gagnon; Molly C Verrier; Jennifer Holmes; Heather Flett; Farnoosh Farahani; S Mohammad Alavinia; Maryam Omidvar; Matheus J Wiest; B Catharine Craven
Journal:  J Spinal Cord Med       Date:  2021       Impact factor: 1.985

10.  Effects of Combined Upper Limb Robotic Therapy in Patients With Tetraplegic Spinal Cord Injury.

Authors:  Joo Hwan Jung; Hye Jin Lee; Duk Youn Cho; Jung-Eun Lim; Bum Suk Lee; Seung Hyun Kwon; Hae Young Kim; Su Jeong Lee
Journal:  Ann Rehabil Med       Date:  2019-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.